Clinical trials: Chagas Disease
Infectious Diseases
Specificity Study of Diagnostic for Chagas Disease
This study assesses the specificity of Chagas Detect™ Plus (CDP) rapid test versus standard reference tests (e.g. RIPA or IFA) for Chagas diagnosis in the US.
- Trial name
- NCT02544139
- Testing
- Chagas Detect Plus
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- InBios International, Inc.
Chagas Disease
Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
Background: Chagas disease is a parasitic infection caused by the Trypanosome cruzi. The initial phase of the infection happens mainly in children. Up to 10% of infected children die.
- Trial name
- NCT00699387
- Testing
- Benznidazole
- Where
- Argentina
- Volunteers
- 37 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Chagas Cardiomyopathy
Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.
The present study aims to evaluate the microvascular endothelial function of a single centre cohort of patients with the cardiac form of Chagas disease, and to search for associations with clinical and laboratory variables.
- Trial name
- NCT03524768
- Testing
- skin laser speckle contrast imaging and video-capillaroscopy
- Where
- Brazil
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Cardiology, Laranjeiras, Brazil
Chagas Disease
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
This study evaluate the efficacy and safety of benznidazole in the treatment of chronic indeterminate Chagas disease in children.
- Trial name
- NCT04024163
- Testing
- Benznidazole
- Where
- 9 sites in Argentina, Bolivia and 1 more
- Volunteers
- 178 people
- Sponsor
- Insud Pharma
Chagas' Disease
Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease
The purpose of this study is to describe the population pharmacokinetics parameters of benznidazole in children with acute or early chronic indeterminate form of Chagas Disease.
- Trial name
- Pop PK Chagas (NCT01549236)
- Testing
- Benznidazole 12,5mg or 100mg
- Where
- 3 sites in Argentina
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Chagas Disease
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission.
- Trial name
- NCT04274101
- Testing
- Clinical Manifestations, Serologic response, Direct method
- Where
- Argentina
- Volunteers
- 900 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Chagas Disease
Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
The investigators are proposing to perform a double-blinded, non-inferiority randomized controlled trial comparing a short 30-day treatment with BZN 150mg/day (30d/150mg) vs. a 60-day treatment with BZN 300 mg/day (60d/300mg).
- Trial name
- BETTY (NCT03672487)
- Testing
- Benznidazole
- Where
- 3 sites in United States, Argentina
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Tulane University School of Public Health and Tropical Medicine
Chagas Disease
Abbott ESA Chagas Assay Post-Market Study
The study is conducted to meet an FDA post market commitment to collect and report data on the performance of the ESA Chagas assay.
- Trial name
- ESA (NCT01662362)
- Testing
- Testing Donor Specimens with ESA Chagas
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Abbott Diagnostics Division
Chagas Disease, Chagas Cardiomyopathy
Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children
Chagas disease (CD) could be acquired by contact with the vector, transplacentally and by blood transfusion. The duration and clinical presentation of the initial acute phase of the infection may be variable, but the majority of…
- Trial name
- NCT04090489
- Where
- Argentina
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Heart Diseases, Myocardial Diseases
Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States
A detailed review was made of data pertinent to the occurrence of chronic Chagas disease in the United States.
- Conditions
- Heart Diseases, Myocardial Diseases, Chagas Disease
- Trial name
- NCT00005455
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Infectious Diseases
Sensitivity Study of Diagnostic for Detection of Chagas Infection
This study is a multi-site trial assessing the sensitivity of Chagas Detect™ Plus rapid test versus standard reference tests (e.g. IFA, IHA, RIPA) for Chagas diagnosis.
- Trial name
- NCT02134548
- Where
- 2 sites in Bolivia, Chile
- Volunteers
- 1,601 people
- Sponsor
- InBios International, Inc.
Chagas Disease
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease).
- Trial name
- NCT02625974
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- 25 sites in Argentina, Bolivia and 1 more
- Volunteers
- 330 people
- Sponsor
- Bayer
Chagas Disease
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied.
- Trial name
- NCT05477953
- Testing
- Nifurtimox (BAYA2502)
- Where
- 12 sites in United States, Argentina and 10 more
- Volunteers
- 50 people
- Sponsor
- Bayer
Chronic Chagas
Prospective Evaluation of Rapid Diagnostic Tests for Trypanosoma Cruzi Infection
Chagas disease (CD) is the most significant endemic zoonosis in Argentina. Two-thirds of affected individuals live in urban areas but only 10% globally are aware of their infection.
- Trial name
- NCT07304349
- Where
- 4 sites in Argentina
- Volunteers
- 3,234 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
Chagas' Disease
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by…
- Trial name
- NCT03784391
- Testing
- Lampit (Nifurtimox, BAYA2502)
- Where
- Argentina
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Chagas Disease, Syphilis
Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases
Chagas disease and syphilis are considered a mayor public health problem worldwide. Both pathologies affect socio-economic vulnerable population and they are both transmitted congenitally, causing an alarming increasing number of…
- Trial name
- NCT04084379
- Where
- Argentina
- Volunteers
- 560 people
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires